



# SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

( 深圳市海普瑞藥業集團股份有限公司 )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock code 股份代號 : 9989)

## NOTIFICATION LETTER 通知信函

Dear Registered Shareholder (s),

December 18, 2023

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company")

- Notice of publication of Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting (the "Current Corporate Communications")

The Board of Directors of the Company has decided to call a shareholders' general meeting of the Company to be held on January 10, 2024 at the HKE Exchange Building, 16 Harbour Road, Kowloon, to accept the Company's 2023 Annual Report and to elect the 2023-2024 Independent Non-executive Directors of the Company.

If you are a shareholder of the Company, you are invited to attend the meeting. To request a Request Form (to be used to request a proxy form) and a ballot paper, please contact the Company's (or its) Secretaries Limited (the Hong Kong Share Registrar) by email at share@hepalink.com.hk or by telephone at Hong Kong. Our telephone office is at the address of the Hong Kong Secretaries Limited, 17/F, Finance Centre, 16 Harbour Road, Hong Kong.

Unless otherwise specified, the above information is for the Company's general information.

Should you have any enquiries, please contact the Company's Secretaries Limited (the Hong Kong Secretaries Limited) at 9:00 a.m. to 6:00 p.m., Monday to Friday, by telephone at (852) 2980 1333.

Yours faithfully,  
Faded signature  
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.  
Li Li  
Chairman

Note 1: The above information is for the Company's general information. For more information, please refer to the Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting (the "Current Corporate Communications") of the Company.

Note 2: The Company's Secretaries Limited (the Hong Kong Secretaries Limited) will be responsible for the following matters: (a) to receive and forward the Request Form and ballot paper to the shareholders; (b) to receive and forward the Request Form and ballot paper to the Company; (c) to receive and forward the Request Form and ballot paper to the Company; (d) to receive and forward the Request Form and ballot paper to the Company; (e) to receive and forward the Request Form and ballot paper to the Company.

致非登記股份持有人(附註1):

深圳市海普瑞藥業集團股份有限公司(「本公司」)  
- 2024年第一次臨時股東大會通函、通告及代表委任表格(「本次公司通訊文件」)之發佈通知

本公司的本次公司通訊文件中、英文版本現已上載於本公司網站 www.hepalink.com.hk 及香港交易所披露易網站 www.hkexnews.hk, 歡迎瀏覽。請在本公司網站主頁的「投資者專區」項下選擇有關文件或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本公司本次及將來所有公司通訊文件(附註2)之印刷本, 請填妥在本信函背面的申請表格(「申請表格」)(該表格亦可於上述網站下載), 並使用申請表格下方的預付費郵寄標籤寄回(如在香港投寄); 否則, 請貼上足夠的郵票。申請表格請經卓佳證券登記有限公司(「香港股份登記處」)寄回本公司, 香港股份登記處的地址為香港夏愨道16號遠東金融中心17樓。

蘇維燾潘儿 & 胸 瑟牌 曾枯 : 鑲欲收取仇社將來訊文件

